Observation study for children 0-5 with LAMA2 muscular dystrophy
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This study follows young children with LAMA2-related congenital muscular dystrophy to learn more about the disease. It does not test a new treatment, so it may help families understand the condition better and prepare for future trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between birth and under 5 years old.
- A doctor must have confirmed LAMA2-related muscular dystrophy through genetic testing or a muscle biopsy.
- Your child cannot have another confirmed genetic disease.
- Your child must keep their current exercise or physical therapy plan during the study.
- Your child cannot have been in another trial or taken an experimental drug (like Losartan) in the last month.
- Your child must not have a serious medical illness or been hospitalized in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.
This study follows people with LAMA2-related muscular dystrophy (a genetic muscle-weakening condition) to learn how it changes over time and find better ways to measure it. By participating, you help researchers identify new disease markers that could improve future treatments.
This study looks at a new protein that might help people with LAMA2-related muscular dystrophy. It uses stored samples to see if the protein could be a useful addition to future treatments.
This study looks at measurements and child-focused outcomes in babies and toddlers with myotonic dystrophy type 1 (DM1) that started in the newborn period. It may help researchers better track how the condition affects children and evaluate care plans more accurately.
This study follows children with LAMA2-related muscular dystrophy to learn how the condition changes over time. It does not test a new treatment, but helps researchers understand the disease better.
This study follows people with LAMA2-related muscular dystrophy or SELENON-related myopathy over 5 years to understand how the condition changes over time. It may help you by tracking your disease progression and contributing to future research.
Hear when a new LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.